Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-Infected Ugandan Women

Next Previous
Trial Profile

A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-Infected Ugandan Women

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etonogestrel (Primary) ; Efavirenz; Nevirapine
  • Indications Pregnancy
  • Focus Pharmacokinetics

Most Recent Events

  • 07 Mar 2018 Results (n=39) assessing the potential associations between single nucleotide polymorphisms involved in efavirenz and etonogestrel metabolism with the observed alteration in etonogestrel pharmacokinetics in women from this study, presented at the 25th Conference on Retroviruses and Opportunistic Infections.
  • 31 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 15 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Feb 2016, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top